Jazz Pharmaceuticals buys Actio Biosciences for $820 million upfront
The deal brings ABS-1230, a potential first-in-class oral treatment for KCNT1-related epilepsy that already has FDA Fast Track designation.
Jazz Pharmaceuticals Acquirer · Actio Biosciences Target